J&J: Brussels approves Actelion deal, on certain conditions.
(CercleFinance.com) - Johnson & Johnson has won antitrust approval to buy Swiss biotechnology company Actelion, under certain conditions, the European Commission said on Friday.
The decision is subject to conditions ensuring that clinical development of their experimental insomnia drugs will not be adversely affected by the merger, Brussels said.
Both Johnson & Johnson and Actelion are currently developing treatments in this area.
In order to address the Commission's conditions, amongst other measures, J&J has granted partner Minerva Neurosciences new rights over the drug's global development.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The decision is subject to conditions ensuring that clinical development of their experimental insomnia drugs will not be adversely affected by the merger, Brussels said.
Both Johnson & Johnson and Actelion are currently developing treatments in this area.
In order to address the Commission's conditions, amongst other measures, J&J has granted partner Minerva Neurosciences new rights over the drug's global development.
Copyright (c) 2017 CercleFinance.com. All rights reserved.